Mathias has led Rentschler Biopharma SE, a global full-service CDMO, since 2016 and brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica.

In addition, Oxford Biomedica announces two changes to its Board, both of which will also take effect on 27th March 2023. Stuart Henderson will become Vice Chair, a newly created position which replaces the previously combined role of Deputy Chair and Senior Independent Director, the position Stuart has filled since June 2020. Professor Dame Kay Davies will assume the role of Senior Independent Director, following her appointment as a Non-Executive Director in March 2021.